SPOTLIGHT: ReNeuron looks to resolve FDA issues


ReNeuron is hoping that a meeting Feb. 14 with FDA officials will resolve the agency's concerns over its ReN001 stem cell therapy, which prompted the agency to put a clinical hold on the therapy. Release